Merck & Co Resumes Islatravir HIV Studies After Safety Concerns, But Abandons PrEP Approach
Maintains Belief In Oral Long-Acting Regimen
After a nine-month US FDA-imposed pause, Merck is relaunching its studies of islatravir with a lower dose, while also abandoning its use in PrEP studies.
